Low Serum Glutathione Peroxidase Activity Increases Risk of Cardiovascular Disease in Individuals with Low HDL-cholesterol
By LabMedica International staff writers Posted on 28 Jun 2012 |
A retrospective study of stored serum samples has found that individuals with low HDL-cholesterol (cholesterol associated with high-density lipoproteins) and low levels of the enzyme glutathione peroxidase (GPx3) suffered significantly more incidence of fatal cardiovascular disease than did those with low HDL-cholesterol but elevated levels of GPx3.
GPx3 is a natural antioxidant that contains a selenocysteine (Sec) residue at its active site. One of its activities in the body is to reduce oxidized lipids, such as LDL (low-density lipoproteins), which have been linked to the development of atherosclerosis. This relationship to cardiovascular disease was the basis for a study conducted by investigators at the University of Minnesota (Minneapolis, USA) to determine whether high GPx3 activity could reduce cardiovascular disease (CVD) mortality.
The investigators evaluated 130 stored serum samples obtained during the Minnesota Heart Survey from participants aged 26-85 years who had died of cardiovascular disease after five to 12 years of follow-up care. Odds ratios (OR) were calculated after adjustment for age, sex, baseline year, body mass index, smoking, alcohol intake, physical activity, total and HDL-cholesterols, systolic blood pressure, serum glucose, and gamma glutamyltransferase (GTT) activity. Data was compared to that from 240 control samples from individuals without cardiovascular disease.
Results published in the June 15, 2012, online edition of the journal PLoS One revealed that individuals with low levels of HDL-cholesterol and GPx3 were six times more likely to die from cardiovascular disease, including heart attack or stroke, than those with low levels of HDL-cholesterol and high levels of GPx3. GPx3 levels were not linked significantly to risk of cardiovascular disease in individuals with high levels of HDL-cholesterol.
“In our study, we found that people with high levels of the GPx3 enzyme and low levels of good cholesterol were six times less likely to develop cardiovascular disease than people with low levels of both,” said senior author Dr. Jordan L. Holtzman, professor of pharmacology and medicine at the University of Minnesota. “This GPx3 enzyme gives us a good reason to believe that natural antioxidants like GPx3 are good for heart health. This is an important enzyme for people with low HDL-cholesterol. We think further research will be important in determining the future role of GPx3 and what drugs may serve to increase its activity in the blood.”
"It is important to point out that people should not rush out to their doctors and demand testing for the GPx3 enzyme,” said Dr. Holtzman. “But in time, we hope that measuring this enzyme will be a common blood test when determining whether a patient is at risk for cardiovascular disease, including heart attacks and strokes.”
Related Links:
University of Minnesota
GPx3 is a natural antioxidant that contains a selenocysteine (Sec) residue at its active site. One of its activities in the body is to reduce oxidized lipids, such as LDL (low-density lipoproteins), which have been linked to the development of atherosclerosis. This relationship to cardiovascular disease was the basis for a study conducted by investigators at the University of Minnesota (Minneapolis, USA) to determine whether high GPx3 activity could reduce cardiovascular disease (CVD) mortality.
The investigators evaluated 130 stored serum samples obtained during the Minnesota Heart Survey from participants aged 26-85 years who had died of cardiovascular disease after five to 12 years of follow-up care. Odds ratios (OR) were calculated after adjustment for age, sex, baseline year, body mass index, smoking, alcohol intake, physical activity, total and HDL-cholesterols, systolic blood pressure, serum glucose, and gamma glutamyltransferase (GTT) activity. Data was compared to that from 240 control samples from individuals without cardiovascular disease.
Results published in the June 15, 2012, online edition of the journal PLoS One revealed that individuals with low levels of HDL-cholesterol and GPx3 were six times more likely to die from cardiovascular disease, including heart attack or stroke, than those with low levels of HDL-cholesterol and high levels of GPx3. GPx3 levels were not linked significantly to risk of cardiovascular disease in individuals with high levels of HDL-cholesterol.
“In our study, we found that people with high levels of the GPx3 enzyme and low levels of good cholesterol were six times less likely to develop cardiovascular disease than people with low levels of both,” said senior author Dr. Jordan L. Holtzman, professor of pharmacology and medicine at the University of Minnesota. “This GPx3 enzyme gives us a good reason to believe that natural antioxidants like GPx3 are good for heart health. This is an important enzyme for people with low HDL-cholesterol. We think further research will be important in determining the future role of GPx3 and what drugs may serve to increase its activity in the blood.”
"It is important to point out that people should not rush out to their doctors and demand testing for the GPx3 enzyme,” said Dr. Holtzman. “But in time, we hope that measuring this enzyme will be a common blood test when determining whether a patient is at risk for cardiovascular disease, including heart attacks and strokes.”
Related Links:
University of Minnesota
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more